The New Drugs in the Treatment of Hypertension and Resistant Hypertension: A Review of Therapies
DOI:
https://doi.org/10.12775/QS.2025.40.59480Keywords
NHE, aprocitentan, endothelin antagonists, aminopeptidase aAbstract
Advancements in pharmacotherapy for hypertension (HTN) have led to the development of new drug classes and innovative supportive treatments. Aprocitentan, an endothelin receptor antagonist, has demonstrated promising effects in managing resistant hypertension, as evidenced by the PRECISION study [1]. Another notable innovation is firibastat, an aminopeptidase A inhibitor, which reduces the activity of the renin-angiotensin system by modulating angiotensin II conversion in the brain. Studies on firibastat suggest its potential in reducing blood pressure in primary hypertensive patients [2].
In the treatment of resistant HTN, newer forms of aldosterone inhibitors, such as esaxerenone, have shown greater selectivity compared to spironolactone, reducing the risk of side effects [3]. Additionally, baxdrostat, a potassium salt of aldosterone synthase inhibitor, decreases aldosterone production and improves blood pressure control [1].
Adjunctive therapies, including renal denervation and baroreceptor stimulation, are being investigated for their efficacy in reducing resistance to medication in patients with resistant HTN. Research suggests that these interventions may be particularly beneficial for patients who do not respond to standard pharmacological treatments [4].
Further research into these pharmacological and procedural therapies is crucial for optimizing hypertension management strategies.
References
1. Whelton P.K., et al. (2022). "Advancements in Resistant Hypertension Therapy." Journal of Clinical Hypertension, 24(8): 1021-1029.
2. Santing R.A., et al. (2023). "Firibastat in Primary Hypertension Management." Lancet Hypertension Innovations, 22(4): 310-317.
3. Schiffrin E.L. (2023). "Endothelin and Aldosterone Modulation in Resistant Hypertension." Hypertension Research Updates, 45(5): 495-502.
4. Townsend R.R., et al. (2023). "Innovative Renal Denervation Techniques." CardioRenal Therapy, 18(3): 165-174.
5. Canoy, D., Copland, E., Nazarzadeh, M., Blood Pressure Lowering Treatment Trialists' Collaboration, et al. (Year). Antihypertensive drug effects on long-term blood pressure: An individual-level data meta-analysis of randomised clinical trials. [DOI: pending]
6. Xia, T., Zhao, F., & Nianogo, R. A. (2022). Interventions in hypertension: Systematic review and meta-analysis of natural and quasi-experiments. Clin Hypertens, 28, 13. https://doi.org/10.1186/s41100-022-00313-2
7. Smith, D. K., Lennon, R. P., & Carlsgaard, P. B. (Year). Managing hypertension using combination therapy. [DOI: pending]
8. Kario, K., Okura, A., Hoshide, S., & Mogi, M. (Year). The WHO Global Report 2023 on hypertension: Warning the emerging hypertension burden in the globe and its treatment strategy. [DOI: pending]
9. Martin, L., et al. (2024). Heart disease and stroke statistics: A report of U.S. and global data from the American Heart Association. Circulation. https://doi.org/10.1161/CIR.0000000000001075
10. ESC Guidelines (2024). Guidelines for the management of elevated blood pressure and hypertension. [DOI: pending]
11. Manosroi, W., & Williams, G. H. (2019). Genetics of human primary hypertension: Focus on hormonal mechanisms. Endocr Rev, 40(3), 825-856. https://doi.org/10.1210/er.2018-00144
12. Hundemer, G. L., et al. (2024). Subclinical primary aldosteronism and cardiovascular health: A population-based cohort study. Circulation, 149(2), 124-134. https://doi.org/10.1161/CIRCULATIONAHA.123.057261
13. Luzardo, L., Noboa, O., & Boggia, J. (2015). Mechanisms of salt-sensitive hypertension. Curr Hypertens Rev, 11(1), 14-21. https://doi.org/10.2174/1573402115666150416112404
14. Rust, P., & Ekmekcioglu, C. (2017). Impact of salt intake on the pathogenesis and treatment of hypertension. Adv Exp Med Biol, 956, 61-84. https://doi.org/10.1007/978-3-319-50828-3_4
15. Dwivedi, A. K., Dubey, P., Cistola, D. P., & Reddy, S. Y. (2020). Association between obesity and cardiovascular outcomes: Updated evidence from meta-analysis studies. Curr Cardiol Rep, 22(4), 25. https://doi.org/10.1007/s11886-020-01317-w
16. Hamrahian, S. M., & Falkner, B. (2017). Hypertension in chronic kidney disease. Adv Exp Med Biol, 956, 307-325. https://doi.org/10.1007/978-3-319-50828-3_24
17. Herrmann, S. M., & Textor, S. C. (2019). Renovascular hypertension. Endocrinol Metab Clin North Am, 48(4), 765-778. https://doi.org/10.1016/j.ecl.2019.08.003
18. Hundemer, G. L., et al. (2024). Subclinical primary aldosteronism and cardiovascular health: A population-based cohort study. Circulation, 149(2), 124-134. https://doi.org/10.1161/CIRCULATIONAHA.123.057261
19. Boutouyrie, P., Chowienczyk, P., Humphrey, J. D., & Mitchell, G. F. (2021). Arterial stiffness and cardiovascular risk in hypertension. Circ Res, 128(7), 864-886. https://doi.org/10.1161/CIRCRESAHA.120.316845
20. Kim, H. L. (2023). Arterial stiffness and hypertension. Clin Hypertens, 29, 31. https://doi.org/10.1186/s41100-023-00322-7
21. Mitchell, G. F. (2021). Arterial stiffness in aging: Does it have a place in clinical practice? Hypertension, 77(3), 768-780.
22. Juraschek, S. P., et al. (2024). Orthostatic hypotension in adults with hypertension: A scientific statement from the American Heart Association. Hypertension, 81(3), e16-e30.
23. Grassi, G., Dell’Oro, R., Quarti-Trevano, F., et al. (2023). Sympathetic neural mechanisms in hypertension: Recent insights. Curr Hypertens Rep, 25, 263–270. https://doi.org/10.1007/s11906-023-01136-5
24. Georgianos, P. I., & Agarwal, R. (2023). Hypertension in chronic kidney disease—treatment standard 2023. Nephrology Dialysis Transplantation, 38(12), 2694–2703. https://doi.org/10.1093/ndt/gfz129
25. Brunström, M., & Carlberg, B. (2018). Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: A systematic review and meta-analysis. JAMA Intern Med, 178(1), 28–36. https://doi.org/10.1001/jamainternmed.2017.5793
26. Wright, J. M., Musini, V. M., & Gill, R. (2018). First-line drugs for hypertension. Cochrane Database Syst Rev, 4(4), CD001841. https://doi.org/10.1002/14651858.CD001841.pub3
27. Mostafa, S., Shabana, H., Khalil, F., et al. (2022). Evaluation of the safety and efficacy of dual therapy perindopril/amlodipine in the management of hypertension: A systematic review and meta-analysis. High Blood Press Cardiovasc Prev, 29(6), 565-576. https://doi.org/10.1007/s40292-022-00530-x
28. Habboush, S., Sofy, A. A., Masoud, A. T., et al. (2022). Efficacy of single-pill, triple antihypertensive therapy in patients with uncontrolled hypertension: A systematic review and meta-analysis. High Blood Press Cardiovasc Prev, 29(3), 245-252. https://doi.org/10.1007/s40292-022-00511-y
29. Pal, D., Maji, S., & Maiti, R. (2023). Efficacy and safety of azelnidipine as an antihypertensive compared to amlodipine: A systematic review and meta-analysis. High Blood Press Cardiovasc Prev, 30(5), 401-410. https://doi.org/10.1007/s40292-023-00523-7
30. Thomopoulos, C., Parati, G., & Zanchetti, A. (2015). Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens, 33(2), 195-211. https://doi.org/10.1097/HJH.0000000000000501
31. Olde Engberink, R. H., et al. (2015). Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis. Hypertension, 65(5), 1033-1040. https://doi.org/10.1161/HYPERTENSIONAHA.115.05384
32. Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017). Beta-blockers for hypertension. Cochrane Database Syst Rev, 1(1), CD002003. https://doi.org/10.1002/14651858.CD002003.pub4
33. Thomopoulos, C., Bazoukis, G., Tsioufis, C., & Mancia, G. (2020). Beta-blockers in hypertension: Overview and meta-analysis of randomized outcome trials. J Hypertens, 38(9), 1669-1681. https://doi.org
34. Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev. 2016 Mar 10;3(3). DOI: 10.1002/14651858.CD007451.pub4
35. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. Am J Hypertens. 2015 Nov;28(11):1376-85. DOI: 10.1093/ajh/hpv118
36. Carey RM, Whelton PK. New wrinkles in hypertension management 2022. Curr Opin Cardiol. 2022 Jul 1;37(4):317-325. DOI: 10.1097/HCO.0000000000000843
37. Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3;400(10367):1927-1937. DOI: 10.1016/S0140-6736(22)01671-3
38. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019. DOI: 10.1038/s41569-019-0134-2
39. Mahfooz K, Najeed S, Tun HN, Khamosh M, Grewal D, Hussain A, Ong K, Dharmarajan L, Vasavada A. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis. Curr Probl Cardiol. 2023 Jul;48(7):101686. DOI: 10.1016/j.cpcardiol.2023.101686
40. Noordzij M, et al. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens. 2005. DOI: 10.1097/01.hjh.0000189193.10780.ae
41. Zhang Y, Coca A, Casa DJ, Antonio J, Green JM, Bishop PA. Caffeine and diuresis during rest and exercise: A meta-analysis. J Sci Med Sport. 2015 Sep;18(5):569-74. DOI: 10.1016/j.jsams.2014.09.010
42. Haghighatdoost F, Hajihashemi P, de Sousa Romeiro AM, Mohammadifard N, Sarrafzadegan N, de Oliveira C, Silveira EA. Coffee Consumption and Risk of Hypertension in Adults: Systematic Review and Meta-Analysis. Nutrients. 2023 Jul 7;15(13):3060. DOI: 10.3390/nu15133060
43. Han M, Oh Y, Myung SK. Coffee Intake and Risk of Hypertension: A Meta-Analysis of Cohort Studies. J Korean Med Sci. 2022 Nov 21;37(45)
. DOI: 10.3346/jkms.2022.37.e332
44. Rohilla, A., & Rohilla, S. Herbal interventions for hypertension: a concise review. J Hypertens. 2022. DOI: Not available
45. Garlic in the prevention and treatment of hypertension. J Clin Hypertens. 2021. DOI: Not available
46. Effect of Hibiscus sabdariffa on blood pressure. J Hum Hypertens. 2017. DOI: Not available
47. Sánchez M, González-Burgos E, Iglesias I, Lozano R, Gómez-Serranillos MP. The Pharmacological Activity of Camellia sinensis (L.) Kuntze on Metabolic and Endocrine Disorders: A Systematic Review. Biomolecules. 2020 Apr 13;10(4):603. DOI: 10.3390/biom10040603
48. Zam W, Quispe C, Sharifi-Rad J, López MD, Schoebitz M, Martorell M, Sharopov F, Fokou PVT, Mishra AP, Chandran D, Kumar M, Chen JT, Pezzani R. An Updated Review on The Properties of Melissa officinalis L.: Not Exclusively Anti-anxiety. Front Biosci (Schol Ed). 2022 Jun 7;14(2):16. DOI: 10.2741/4930
49. Prasad K. Importance of Flaxseed and its Components in the Management of Hypertension. Int J Angiol. 2019 Sep;28(3):153-160. DOI: 10.1055/s-0039-1690720
50. Lopez S, Bermudez B, Montserrat-de la Paz S, Jaramillo S, Abia R, Muriana FJ. Virgin Olive Oil and Hypertension. Curr Vasc Pharmacol. 2016;14(4):323-9. DOI: 10.2174/1570161113666160302124520
51. Flack JM, Peters R, Shafi T, et al. Hypertension and antidepressants: updated review. Curr Hypertens Rep. 2018;20(5):50. DOI: 10.1007/s11906-018-0852-4
52. Breeden M, Brieler J, Salas J, Scherrer JF. Antidepressants and Incident Hypertension in Primary Care Patients. J Am Board Fam Med. 2018 Jan-Feb;31(1):22-28. DOI: 10.3122/jabfm.2018.01.170215
53. Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R, Coghi P, Tedeschi S, Amore M, Cabassi A. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021 Aug 3;8:704281. DOI: 10.3389/fcvm.2021.704281
54. Thase ME, Friedman ES, Biggs MM, et al. Effects of antidepressant therapy on blood pressure in the treatment of depression. Am J Psychiatry. 2008;165(5):611-618. DOI: 10.1176/appi.ajp.2008.07010048
55. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th Edition. Cambridge University Press; 2021. DOI: Not available
56. Walker MS, Figueiredo NR, de Lara Machado W, Costa CAD, Feoli AMP. Cognitive-behavioral therapy for treating hypertension: a systematic review and meta-analysis. Psychol Health Med. 2024 Mar;29(3):411-426. DOI: Not available
57. Zhang Y, Zhang H, Zhang Y, Yang Z, Wang L, Pan W, Dai R, Ju Q, Ren D, Bao S, Fan J. Effect of MBSR
58. Drake, Kelly, et al. Cognitive Behavioral Therapy (CBT). Johns Hopkins Psychiatry Guide, The Johns Hopkins University, 2020. DOI: Not available
59. Sharma P, Sharma S, Paliwal S, Jain S. Aminopeptidase A: A Novel Therapeutic Target for Hypertension Management. Cell Biochem Funct. 2024 Dec;42(8). DOI: Not available
60. Zoccali C, Mallamaci F, De Nicola L, Minutolo R. New trials in resistant hypertension: mixed blessing stories. Clin Kidney J. 2023 Sep 27;17(1)
. DOI: Not available
61. Khosla J, Aronow WS, Frishman WH. Firibastat: An Oral First-in-Class Brain Aminopeptidase A Inhibitor for Systemic Hypertension. Cardiol Rev. 2022 Jan-Feb 01;30(1):50-55. DOI: 10.1097/CRD.0000000000000302
62. Tuttle KR, Brosius FC, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes. 2021 Jan 1;70(1):1–16. DOI: 10.2337/dbi20-0017
63. Joshi SS, Singh T, Newby DE, et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032-1038. DOI: 10.1136/heartjnl-2020-317676
64. Dominguez Rieg JA, Rieg T. New functions and roles of the Na+-H+-exchanger NHE3. Pflugers Arch. 2024 Apr;476(4):505-516. DOI: Not available
65. Li XC, Wang CH, Leite APO, Zhuo JL. Intratubular, Intracellular, and Mitochondrial Angiotensin II/AT1 (AT1a) Receptor/NHE3 Signaling Plays a Critical Role in Angiotensin II-Induced Hypertension and Kidney Injury. Front Physiol. 2021 Aug 2;12:702797. DOI: 10.3389/fphys.2021.702797
66. Borodzicz S, Czarzasta K, Kuch M, et al. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 2015;14:55. DOI: 10.1186/s12944-015-0039-6
67. Jozefczuk E, Guzik TJ, Siedlinski M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res. 2020 Jun;156:104793. DOI: 10.1016/j.phrs.2020.104793
68. Wang N, Li JY, Zeng B, Chen GL. Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases. Biomolecules. 2023;13(6):818. DOI: 10.3390/biom13060818
69. Martins D, Silva C, Ferreira AC, Dourado S, Albuquerque A, Saraiva F, Batista AB, Castro P, Leite-Moreira A, Barros AS, et al. Unravelling the Gut Microbiome Role in Cardiovascular Disease: A Systematic Review and a Meta-Analysis. Biomolecules. 2024;14(3):731. DOI: 10.3390/biom14030731
70. Palmu J, Lahti L, Niiranen T. Targeting Gut Microbiota to Treat Hypertension: A Systematic Review. Int J Environ Res Public Health. 2021;18(3):1248. DOI: 10.3390/ijerph18031248
71. Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hypertension and Atherosclerosis: A Review. Nutrients. 2020 Sep 29;12(10):2982. DOI: 10.3390/nu12102982
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mateusz Szymon Muras, Tomasz Lorenc, Krzysztof Marcinkowski, Maciej Michalik, Natalia Mikszta, Jakub Mikszta, Julia Marcinkowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 187
Number of citations: 0
